The migration of an implantable loop recorder (ILR) is a rare complication. We aimed to perform a meta-summary of case reports to characterize patients who experienced an ILR migration. We searched for case reports published in PubMed, Google Scholar, Scopus, and Embase from January 2017 to 2023 using the following keywords: "migration ILR," "migration loop recorder," "complication loop recorder," and "complication ILR." Seven case reports/case series reporting ILR migration were included. Data about patients' characteristics, ILR implantation, time of onset, management, and clinical outcome of this complication were collected. Seven patients who experienced the migration of an ILR were examined. All patients experienced migration within 35 days following ILR implantation. The clinical suspicion of ILR migration mainly arose from patients' symptomatology. The migration of the ILR was confirmed by a radiological scan in all cases, and surgical removal, preferably by video-assisted thoracic surgery, was required. In conclusion, intrapleural migration is a rare complication of ILR implantation. It may occur in the early postprocedural period. Clinical suspicion arises from symptoms, but a radiological scan is necessary to confirm the diagnosis. Surgical removal is mandatory.
{"title":"Migration of an Implantable Loop Recorder: A Meta-summary of Case Reports.","authors":"Alfredo Mauriello, Anna Rago, Dario Amore, Giacomo Sica, Antonello D'Andrea, Vincenzo Russo","doi":"10.19102/icrm.2025.16056","DOIUrl":"10.19102/icrm.2025.16056","url":null,"abstract":"<p><p>The migration of an implantable loop recorder (ILR) is a rare complication. We aimed to perform a meta-summary of case reports to characterize patients who experienced an ILR migration. We searched for case reports published in PubMed, Google Scholar, Scopus, and Embase from January 2017 to 2023 using the following keywords: \"migration ILR,\" \"migration loop recorder,\" \"complication loop recorder,\" and \"complication ILR.\" Seven case reports/case series reporting ILR migration were included. Data about patients' characteristics, ILR implantation, time of onset, management, and clinical outcome of this complication were collected. Seven patients who experienced the migration of an ILR were examined. All patients experienced migration within 35 days following ILR implantation. The clinical suspicion of ILR migration mainly arose from patients' symptomatology. The migration of the ILR was confirmed by a radiological scan in all cases, and surgical removal, preferably by video-assisted thoracic surgery, was required. In conclusion, intrapleural migration is a rare complication of ILR implantation. It may occur in the early postprocedural period. Clinical suspicion arises from symptoms, but a radiological scan is necessary to confirm the diagnosis. Surgical removal is mandatory.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 5","pages":"6292-6296"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-15eCollection Date: 2025-05-01DOI: 10.19102/icrm.2025.16055
Maci Clark, Hannah Zerr, Ben Ose, David Fritz, Caroline Trupp, Amulya Gupta, Ahmed Shahab, Amit Noheria, Seth H Sheldon
Left bundle branch area pacing (LBBAP) has shown promising outcomes at experienced centers; however, less is known about the learning curve with initial adoption of LBBAP implantation. We conducted a retrospective analysis (2020-2023) of the learning curve for LBBAP at an academic medical center. Procedural success and device-related adverse events in adult patients undergoing LBBAP by seven new operators with >5 years' experience in device implantation were compared between operators with a history of ≤10 (LBBAPinexp) versus >10 (LBBAPexp) LBBAP implant attempts. Successful LBBAP was defined as a left ventricular activation time (LVAT) of ≤80 ms. Seven operators implanted LBBAP devices in 288 patients (age, 73 ± 11 years; 38% women), including 68 (24%) in the LBBAPinexp group versus 220 (76%) patients in the LBBAPexp group with similar baseline characteristics. The median number of implants per operator was 22 (range, 8-83). Post-implant LVAT ≤ 80 ms was less frequent in LBBAPinexp compared to LBBAPexp (56.9% vs 72.4%; P = .04). There were no significant differences in paced QRS duration ≤ 130 ms (75.9% vs. 76.1%; P = 1.0) or operator self-identified success (85% vs. 91%; P = .2). With new single-/dual-chamber device implants, there was no difference in implant duration (103.4 ± 31.8 vs. 101.6 ± 38.5 min; P = .3), but there was longer fluoroscopy with LBBAPinexp (12.6 ± 10.1 vs. 8.2 ± 8.0 min; P < .0001). The average number of attempts at LBBAP was lower with LBBAPinexp versus LBBAPexp (2.0 ± 1.5 vs. 2.9 ± 2.9; P = .03). There was no difference in device-related adverse events between the two groups (P = .3). Operators use less fluoroscopy, make more attempts at LBBAP, and more frequently achieve LVAT ≤ 80 ms after their first 10 implants.
左束支区起搏(LBBAP)在经验丰富的中心显示出良好的效果;然而,对于最初采用LBBAP植入的学习曲线知之甚少。我们对某学术医疗中心LBBAP的学习曲线进行了回顾性分析(2020-2023年)。我们比较了7位具有5年LBBAP植入经验的新操作者在LBBAP植入史≤10 (LBBAPinexp)和> (LBBAPexp) LBBAP植入史的操作者在LBBAP植入史上的手术成功率和器械相关不良事件。LBBAP成功定义为左心室激活时间(LVAT)≤80 ms。7名手术人员植入LBBAP装置288例(年龄73±11岁;其中,基线特征相似的LBBAPinexp组68例(24%),LBBAPexp组220例(76%)。每位手术者植入物的中位数为22(范围8-83)。植入后LVAT≤80 ms在LBBAPinexp组的发生率低于LBBAPinexp组(56.9% vs 72.4%;P = .04)。节律性QRS持续时间≤130 ms无显著差异(75.9% vs. 76.1%;P = 1.0)或操作者自我识别的成功率(85% vs 91%;P = .2)。使用新的单腔/双腔器械种植体,种植时间无差异(103.4±31.8 vs 101.6±38.5 min);P = .3),但使用LBBAPinexp的透视时间较长(12.6±10.1 vs 8.2±8.0 min;P < 0.0001)。LBBAPinexp对LBBAPexp的平均尝试次数较低(2.0±1.5比2.9±2.9;P = .03)。两组患者器械相关不良事件发生率无差异(P = .3)。操作者较少使用透视检查,对LBBAP进行更多尝试,并且在前10次植入后更频繁地达到LVAT≤80 ms。
{"title":"Learning Curve for Left Bundle Branch Area Pacing Lead Implantation.","authors":"Maci Clark, Hannah Zerr, Ben Ose, David Fritz, Caroline Trupp, Amulya Gupta, Ahmed Shahab, Amit Noheria, Seth H Sheldon","doi":"10.19102/icrm.2025.16055","DOIUrl":"10.19102/icrm.2025.16055","url":null,"abstract":"<p><p>Left bundle branch area pacing (LBBAP) has shown promising outcomes at experienced centers; however, less is known about the learning curve with initial adoption of LBBAP implantation. We conducted a retrospective analysis (2020-2023) of the learning curve for LBBAP at an academic medical center. Procedural success and device-related adverse events in adult patients undergoing LBBAP by seven new operators with >5 years' experience in device implantation were compared between operators with a history of ≤10 (LBBAP<sub>inexp</sub>) versus >10 (LBBAP<sub>exp</sub>) LBBAP implant attempts. Successful LBBAP was defined as a left ventricular activation time (LVAT) of ≤80 ms. Seven operators implanted LBBAP devices in 288 patients (age, 73 ± 11 years; 38% women), including 68 (24%) in the LBBAP<sub>inexp</sub> group versus 220 (76%) patients in the LBBAP<sub>exp</sub> group with similar baseline characteristics. The median number of implants per operator was 22 (range, 8-83). Post-implant LVAT ≤ 80 ms was less frequent in LBBAP<sub>inexp</sub> compared to LBBAP<sub>exp</sub> (56.9% vs 72.4%; <i>P</i> = .04). There were no significant differences in paced QRS duration ≤ 130 ms (75.9% vs. 76.1%; <i>P</i> = 1.0) or operator self-identified success (85% vs. 91%; <i>P</i> = .2). With new single-/dual-chamber device implants, there was no difference in implant duration (103.4 ± 31.8 vs. 101.6 ± 38.5 min; <i>P</i> = .3), but there was longer fluoroscopy with LBBAP<sub>inexp</sub> (12.6 ± 10.1 vs. 8.2 ± 8.0 min; <i>P</i> < .0001). The average number of attempts at LBBAP was lower with LBBAP<sub>inexp</sub> versus LBBAP<sub>exp</sub> (2.0 ± 1.5 vs. 2.9 ± 2.9; <i>P</i> = .03). There was no difference in device-related adverse events between the two groups (<i>P</i> = .3). Operators use less fluoroscopy, make more attempts at LBBAP, and more frequently achieve LVAT ≤ 80 ms after their first 10 implants.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 5","pages":"6284-6291"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-15eCollection Date: 2025-05-01DOI: 10.19102/icrm.2025.16052
Wissam Harmouch, Servando Cuellar, Arun Narayanan, Haider Al Taii, Muhie Dean Sabayon
Intracardiac echocardiography (ICE) is a common tool that has real-time impact in novel pulsed-field ablation (PFA). It is a feasible and efficient option due to zero-fluoroscopy, real-time tissue visualization of procedural maneuvers, and for the assessment of potential procedural complications. We present a case of zero-fluoroscopy-based PFA using four-dimensional (4D) ICE in a 68-year-old man with symptomatic atrial fibrillation. Using 4D ICE, we were able to achieve procedural success by visualization of direct tissue contact with the Farawave™ catheter (Boston Scientific, Marlborough, MA, USA) with each rotation and application of the basket and flower configurations and no edema or color change in tissue morphology after applications. Overall, zero fluoroscopy in PFA is feasible and efficient.
{"title":"An Antiquated Concept in the Novel Era of Ablation: Zero-fluoroscopy Pulsed Field Ablation for Treatment of Atrial Fibrillation.","authors":"Wissam Harmouch, Servando Cuellar, Arun Narayanan, Haider Al Taii, Muhie Dean Sabayon","doi":"10.19102/icrm.2025.16052","DOIUrl":"10.19102/icrm.2025.16052","url":null,"abstract":"<p><p>Intracardiac echocardiography (ICE) is a common tool that has real-time impact in novel pulsed-field ablation (PFA). It is a feasible and efficient option due to zero-fluoroscopy, real-time tissue visualization of procedural maneuvers, and for the assessment of potential procedural complications. We present a case of zero-fluoroscopy-based PFA using four-dimensional (4D) ICE in a 68-year-old man with symptomatic atrial fibrillation. Using 4D ICE, we were able to achieve procedural success by visualization of direct tissue contact with the Farawave™ catheter (Boston Scientific, Marlborough, MA, USA) with each rotation and application of the basket and flower configurations and no edema or color change in tissue morphology after applications. Overall, zero fluoroscopy in PFA is feasible and efficient.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 5","pages":"6268-6270"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-15eCollection Date: 2025-05-01DOI: 10.19102/icrm.2025.16054
Can Menemencioglu, Uğur Canpolat
Cardiac resynchronization therapy (CRT) via left bundle branch area pacing (LBBAP) has emerged as effective and safe as conventional CRT. Left-sided CRT implantation in patients with persistent left superior vena cava (PLSVC) is challenging and impossible in some patients. Right-sided CRT implantation, either conventional or LBBAP, is also tricky, as the delivery sheaths are feasible for left-sided implantations. Here, we present a patient with PLSVC who underwent successful right-sided CRT implantation via LBBAP.
{"title":"Right-sided Cardiac Resynchronization Therapy via Left Bundle Branch Area Pacing in a Patient with Persistent Left Superior Vena Cava.","authors":"Can Menemencioglu, Uğur Canpolat","doi":"10.19102/icrm.2025.16054","DOIUrl":"10.19102/icrm.2025.16054","url":null,"abstract":"<p><p>Cardiac resynchronization therapy (CRT) via left bundle branch area pacing (LBBAP) has emerged as effective and safe as conventional CRT. Left-sided CRT implantation in patients with persistent left superior vena cava (PLSVC) is challenging and impossible in some patients. Right-sided CRT implantation, either conventional or LBBAP, is also tricky, as the delivery sheaths are feasible for left-sided implantations. Here, we present a patient with PLSVC who underwent successful right-sided CRT implantation via LBBAP.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 5","pages":"6278-6283"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-15eCollection Date: 2025-05-01DOI: 10.19102/icrm.2025.16053
Jashan Gill, Ahmad Harb, Jobin Varghese, Rezwan Munshi, Michael T Spooner
Increased age is associated with increased frailty and often worse postoperative outcomes. We sought to assess the safety of leadless pacemaker (LPM) insertion in the very elderly population. We queried the National Readmission Database for patients who underwent LPM insertion from 2017 to 2020. Patients aged ≥90 years were included in the nonagenarian group and compared to patients aged <90 years. Patient comorbidities were queried using the appropriate International Classification of Diseases, Tenth Revision, codes. We compared outcomes using multivariate logistic and linear regression, adjusting for patient comorbidities. At baseline, nonagenarians had higher prevalence rates of hypertension, a history of stroke, atrial fibrillation, atrial flutter, dementia, and hypothyroidism. The control group had more diabetes, coronary artery disease, chronic kidney disease, chronic pulmonary disease, oxygen use, coagulopathy, anemia, obesity, substance abuse, and chronic liver disease. Compared to controls, nonagenarians were found to have a shorter length of stay (2.5 days; P < .001); lower mortality (adjusted odds ratio [aOR], 0.7; P = .02); and lower rates of post-procedural cardiac arrest (aOR, 0.3; P = .03), mechanical ventilation (aOR, 0.4; P < .001), and vasopressor use (aOR, 0.6; P = .001). Nonagenarians were only found to have an increased risk of pericardial complications (tamponade, pericardiocentesis, hemopericardium) (aOR, 1.6; P = .02). There was no significant difference in 30-day readmissions (aOR, 0.97; P = .7), postoperative bleed (aOR, 0.84; P = .07), or stroke (aOR, 0.586; P = .1). Our study demonstrates that LPM insertion could be safe in the very elderly population. However, our study likely demonstrates survivorship bias, as patients in the nonagenarian group had fewer overall comorbidities. Despite adjustment for known comorbidities, there remain confounders that are difficult to account for. Age itself does not seem to be a risk factor for worse outcomes in this population.
{"title":"Safety of Leadless Pacemaker Insertion in Nonagenarians.","authors":"Jashan Gill, Ahmad Harb, Jobin Varghese, Rezwan Munshi, Michael T Spooner","doi":"10.19102/icrm.2025.16053","DOIUrl":"10.19102/icrm.2025.16053","url":null,"abstract":"<p><p>Increased age is associated with increased frailty and often worse postoperative outcomes. We sought to assess the safety of leadless pacemaker (LPM) insertion in the very elderly population. We queried the National Readmission Database for patients who underwent LPM insertion from 2017 to 2020. Patients aged ≥90 years were included in the nonagenarian group and compared to patients aged <90 years. Patient comorbidities were queried using the appropriate International Classification of Diseases, Tenth Revision, codes. We compared outcomes using multivariate logistic and linear regression, adjusting for patient comorbidities. At baseline, nonagenarians had higher prevalence rates of hypertension, a history of stroke, atrial fibrillation, atrial flutter, dementia, and hypothyroidism. The control group had more diabetes, coronary artery disease, chronic kidney disease, chronic pulmonary disease, oxygen use, coagulopathy, anemia, obesity, substance abuse, and chronic liver disease. Compared to controls, nonagenarians were found to have a shorter length of stay (2.5 days; <i>P</i> < .001); lower mortality (adjusted odds ratio [aOR], 0.7; <i>P</i> = .02); and lower rates of post-procedural cardiac arrest (aOR, 0.3; <i>P</i> = .03), mechanical ventilation (aOR, 0.4; <i>P</i> < .001), and vasopressor use (aOR, 0.6; <i>P</i> = .001). Nonagenarians were only found to have an increased risk of pericardial complications (tamponade, pericardiocentesis, hemopericardium) (aOR, 1.6; <i>P</i> = .02). There was no significant difference in 30-day readmissions (aOR, 0.97; <i>P</i> = .7), postoperative bleed (aOR, 0.84; <i>P</i> = .07), or stroke (aOR, 0.586; <i>P</i> = .1). Our study demonstrates that LPM insertion could be safe in the very elderly population. However, our study likely demonstrates survivorship bias, as patients in the nonagenarian group had fewer overall comorbidities. Despite adjustment for known comorbidities, there remain confounders that are difficult to account for. Age itself does not seem to be a risk factor for worse outcomes in this population.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 5","pages":"6272-6277"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We sought to clarify the impacts of premature atrial contractions (PACs) and biochemical markers early after cryoballoon (CB) versus radiofrequency (RF) ablation for atrial fibrillation (AF) on the late recurrence of AF (LRAF). The study population included 138 patients who underwent first-time ablation for paroxysmal AF with CB (n = 69) or RF (n = 69). We compared the levels of the PAC burden on Holter monitoring, myocardial-bound creatine kinase (CK-MB), troponin T (TnT), and C-reactive protein (CRP) the day after ablation, and we assessed the incidence of LRAF, which was defined as AF after a 3-month blanking period. The postprocedural PAC burden was not significantly different between the CB and RF groups (P = .35), whereas the CK-MB and CRP levels were significantly higher in the CB group (both P < .01); the TnT levels of the groups were similar (P = .63). Among these, only a higher PAC burden was significantly associated with LRAF in both the CB (top quartile [≥2.16%]: 58% vs. others: 17%; log-rank P = .01) and RF (top quartile [≥3.05%]: 36% vs. others: 9%; log-rank P < .01) groups. A Cox regression analysis revealed two significant predictors of LRAF: in-hospital recurrence (CB group: hazard ratio [HR], 3.55 [1.67-11.80]; P = .04; RF group: HR, 7.55 [1.67-34.20]; P = .01) and a higher postprocedural PAC burden (CB: HR, 1.54 [1.06-2.22]; P = .02; RF: HR, 1.90 [1.16-3.35]; P = .01). In conclusion, irrespective of the ablation modality, the next-day PAC burden (but not the biochemical markers examined herein) is useful for predicting LRAF. Early AF recurrence should be considered a future risk even at the beginning of the blanking period.
{"title":"Impacts of Premature Atrial Contractions and Biochemical Markers Early After Cryoballoon Versus Radiofrequency Ablation on the Late Recurrence of Atrial Fibrillation.","authors":"Kenichi Sasaki, Daisuke Togashi, Akira Kasagawa, Ikutaro Nakajima, Takumi Higuma, Tomoo Harada, Yoshihiro J Akashi","doi":"10.19102/icrm.2025.16043","DOIUrl":"https://doi.org/10.19102/icrm.2025.16043","url":null,"abstract":"<p><p>We sought to clarify the impacts of premature atrial contractions (PACs) and biochemical markers early after cryoballoon (CB) versus radiofrequency (RF) ablation for atrial fibrillation (AF) on the late recurrence of AF (LRAF). The study population included 138 patients who underwent first-time ablation for paroxysmal AF with CB (<i>n</i> = 69) or RF (<i>n</i> = 69). We compared the levels of the PAC burden on Holter monitoring, myocardial-bound creatine kinase (CK-MB), troponin T (TnT), and C-reactive protein (CRP) the day after ablation, and we assessed the incidence of LRAF, which was defined as AF after a 3-month blanking period. The postprocedural PAC burden was not significantly different between the CB and RF groups (<i>P</i> = .35), whereas the CK-MB and CRP levels were significantly higher in the CB group (both <i>P</i> < .01); the TnT levels of the groups were similar (<i>P</i> = .63). Among these, only a higher PAC burden was significantly associated with LRAF in both the CB (top quartile [≥2.16%]: 58% vs. others: 17%; log-rank <i>P</i> = .01) and RF (top quartile [≥3.05%]: 36% vs. others: 9%; log-rank <i>P</i> < .01) groups. A Cox regression analysis revealed two significant predictors of LRAF: in-hospital recurrence (CB group: hazard ratio [HR], 3.55 [1.67-11.80]; <i>P</i> = .04; RF group: HR, 7.55 [1.67-34.20]; <i>P</i> = .01) and a higher postprocedural PAC burden (CB: HR, 1.54 [1.06-2.22]; <i>P</i> = .02; RF: HR, 1.90 [1.16-3.35]; <i>P</i> = .01). In conclusion, irrespective of the ablation modality, the next-day PAC burden (but not the biochemical markers examined herein) is useful for predicting LRAF. Early AF recurrence should be considered a future risk even at the beginning of the blanking period.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 4","pages":"6251-6259"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12002004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-15eCollection Date: 2025-04-01DOI: 10.19102/icrm.2025.16042
Johnathon Rast, Grant Whitebloom, Omar M Makram, Priyanshu Nain, Lakshya Seth, Nathaniel Wayne, Patrick Houlihan, Alexander Warner, Daniel Sohinki
Dofetilide is a class III anti-arrhythmic medication approved for patients with atrial fibrillation to maintain sinus rhythm. Excessive QTc interval prolongation, a potential side effect of dofetilide, increases the risk of torsades de pointes. This risk is mitigated by closely monitoring the QTc interval during an inpatient initiation protocol for the first five doses. Prior studies have demonstrated that dofetilide can be safely used in patients with heart failure after completing the initiation protocol. However, no studies have investigated risk factors associated with dofetilide-induced excessive QTc interval prolongation, resulting in discontinuation of the medicine. This single-center retrospective cohort study analyzed the association between dofetilide-associated excessive QTc prolongation during medication initiation and pertinent medical comorbidities as well as various echocardiographic values of interest. Risk factors found to be significantly associated with excessive QTc prolongation during dofetilide initiation included a clinical history of heart failure, reduced left ventricular ejection fraction, increased left ventricular end-diastolic diameter, increased left atrial diameter, and reduced right ventricular systolic function. Although some studies have demonstrated the safety of dofetilide use in patients with heart failure, our findings suggest that these patients are less likely to tolerate initiation of the medication due to excessive QTc prolongation.
{"title":"Risk Factors Associated with Unsuccessful Dofetilide Initiation Due to Excessive QT Interval Prolongation: A Retrospective Study.","authors":"Johnathon Rast, Grant Whitebloom, Omar M Makram, Priyanshu Nain, Lakshya Seth, Nathaniel Wayne, Patrick Houlihan, Alexander Warner, Daniel Sohinki","doi":"10.19102/icrm.2025.16042","DOIUrl":"https://doi.org/10.19102/icrm.2025.16042","url":null,"abstract":"<p><p>Dofetilide is a class III anti-arrhythmic medication approved for patients with atrial fibrillation to maintain sinus rhythm. Excessive QTc interval prolongation, a potential side effect of dofetilide, increases the risk of torsades de pointes. This risk is mitigated by closely monitoring the QTc interval during an inpatient initiation protocol for the first five doses. Prior studies have demonstrated that dofetilide can be safely used in patients with heart failure after completing the initiation protocol. However, no studies have investigated risk factors associated with dofetilide-induced excessive QTc interval prolongation, resulting in discontinuation of the medicine. This single-center retrospective cohort study analyzed the association between dofetilide-associated excessive QTc prolongation during medication initiation and pertinent medical comorbidities as well as various echocardiographic values of interest. Risk factors found to be significantly associated with excessive QTc prolongation during dofetilide initiation included a clinical history of heart failure, reduced left ventricular ejection fraction, increased left ventricular end-diastolic diameter, increased left atrial diameter, and reduced right ventricular systolic function. Although some studies have demonstrated the safety of dofetilide use in patients with heart failure, our findings suggest that these patients are less likely to tolerate initiation of the medication due to excessive QTc prolongation.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 4","pages":"6240-6246"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12002000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-15eCollection Date: 2025-04-01DOI: 10.19102/icrm.2025.16045
Ibrahim Alshaghdali, Tyler Alderson, Hakan Paydak, John Paul Mounsey, Subodh Devabhaktuni
Bundle branch re-entrant (BBR) tachycardia is an uncommon form of ventricular tachycardia (VT). This arrhythmia typically occurs in patients with a structural heart disease, especially dilated cardiomyopathy, and significant conduction system impairment, although affected patients with a structurally normal heart or normal conduction system have been reported. The QRS morphology during tachycardia can vary; it typically has a left bundle branch block (LBBB) morphology in which the antegrade conduction is over the right bundle and the retrograde limb is over the left bundle. The reverse of this circuit results in a right bundle branch block (RBBB) QRS morphology. A re-entrant circuit also can utilize interfascicular conduction, such as antegrade conduction over the left anterior fascicle and retrograde conduction up the left posterior fascicle or vice versa. Although there are reports of BBR tachycardia and interfascicular VT occurring in the same patient, to our knowledge, there are no prior reports of BBR tachycardia that has both LBBB and RBBB morphologies in the same patient. This case illustrated a BBR tachycardia with both left bundle and right bundle branch morphologies occurring in a patient with a non-dilated left ventricle.
{"title":"Dual-morphology Bundle Branch Re-entrant Ventricular Tachycardia in Non-dilated Cardiomyopathy.","authors":"Ibrahim Alshaghdali, Tyler Alderson, Hakan Paydak, John Paul Mounsey, Subodh Devabhaktuni","doi":"10.19102/icrm.2025.16045","DOIUrl":"https://doi.org/10.19102/icrm.2025.16045","url":null,"abstract":"<p><p>Bundle branch re-entrant (BBR) tachycardia is an uncommon form of ventricular tachycardia (VT). This arrhythmia typically occurs in patients with a structural heart disease, especially dilated cardiomyopathy, and significant conduction system impairment, although affected patients with a structurally normal heart or normal conduction system have been reported. The QRS morphology during tachycardia can vary; it typically has a left bundle branch block (LBBB) morphology in which the antegrade conduction is over the right bundle and the retrograde limb is over the left bundle. The reverse of this circuit results in a right bundle branch block (RBBB) QRS morphology. A re-entrant circuit also can utilize interfascicular conduction, such as antegrade conduction over the left anterior fascicle and retrograde conduction up the left posterior fascicle or vice versa. Although there are reports of BBR tachycardia and interfascicular VT occurring in the same patient, to our knowledge, there are no prior reports of BBR tachycardia that has both LBBB and RBBB morphologies in the same patient. This case illustrated a BBR tachycardia with both left bundle and right bundle branch morphologies occurring in a patient with a non-dilated left ventricle.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 4","pages":"6260-6267"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12002003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-15eCollection Date: 2025-04-01DOI: 10.19102/icrm.2025.16046
Devi Nair
{"title":"Letter from the Editor in Chief.","authors":"Devi Nair","doi":"10.19102/icrm.2025.16046","DOIUrl":"https://doi.org/10.19102/icrm.2025.16046","url":null,"abstract":"","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 4","pages":"A7-A8"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-15eCollection Date: 2025-04-01DOI: 10.19102/icrm.2025.16041
Parth Sushil Bajoria, Vinod Nookala
Digoxin, a cardiac glycoside and sodium-potassium adenosine triphosphatase inhibitor, has a narrow therapeutic index and is primarily prescribed for conditions such as systolic heart failure and atrial fibrillation. This narrow window increases the risk of toxicity, especially among susceptible populations. Although digoxin use has declined in recent decades and cases of toxicity have become less frequent, clinicians must remain vigilant, particularly with geriatric patients, who are more susceptible due to polypharmacy and reduced renal function. Here, we present a case of a 77-year-old woman with dementia who exhibited elevated digoxin levels and was successfully treated with digoxin immune Fab. While the use of immune Fab in chronic toxicity cases remains uncertain, our retrospective review of similar cases, managed both with and without immune Fab, provides insights into its role and limitations. We further underscore the importance of regular digoxin monitoring rather than checking the levels only during toxic episodes, as consistent monitoring can prevent fatal cases and reduce overall mortality.
{"title":"Digoxin Dilemma: Diagnosing Toxicity Amidst Dementia.","authors":"Parth Sushil Bajoria, Vinod Nookala","doi":"10.19102/icrm.2025.16041","DOIUrl":"https://doi.org/10.19102/icrm.2025.16041","url":null,"abstract":"<p><p>Digoxin, a cardiac glycoside and sodium-potassium adenosine triphosphatase inhibitor, has a narrow therapeutic index and is primarily prescribed for conditions such as systolic heart failure and atrial fibrillation. This narrow window increases the risk of toxicity, especially among susceptible populations. Although digoxin use has declined in recent decades and cases of toxicity have become less frequent, clinicians must remain vigilant, particularly with geriatric patients, who are more susceptible due to polypharmacy and reduced renal function. Here, we present a case of a 77-year-old woman with dementia who exhibited elevated digoxin levels and was successfully treated with digoxin immune Fab. While the use of immune Fab in chronic toxicity cases remains uncertain, our retrospective review of similar cases, managed both with and without immune Fab, provides insights into its role and limitations. We further underscore the importance of regular digoxin monitoring rather than checking the levels only during toxic episodes, as consistent monitoring can prevent fatal cases and reduce overall mortality.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"16 4","pages":"6235-6238"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12002001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}